4D Molecular Therapeutics, Inc.
FDMT
$26.38
$0.000.00%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -19.00K | 20.20M | 239.00K | 298.00K | 1.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.00K | 20.20M | 239.00K | 298.00K | 1.25M |
| Cost of Revenue | -61.33M | 25.07M | 23.58M | 22.41M | -49.53M |
| Gross Profit | 61.31M | -4.86M | -23.35M | -22.11M | 50.78M |
| SG&A Expenses | 10.61M | 9.11M | 8.79M | 7.99M | 8.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.63M | 34.18M | 32.38M | 30.40M | 29.97M |
| Operating Income | -36.65M | -13.97M | -32.14M | -30.11M | -28.72M |
| Income Before Tax | -32.28M | -10.26M | -29.62M | -28.68M | -27.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.28M | -10.26M | -29.62M | -28.68M | -27.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.28M | -10.26M | -29.62M | -28.68M | -27.38M |
| EBIT | -36.65M | -13.97M | -32.14M | -30.11M | -28.72M |
| EBITDA | -35.55M | -12.98M | -31.06M | -29.08M | -27.71M |
| EPS Basic | -0.75 | -0.24 | -0.77 | -0.88 | -0.84 |
| Normalized Basic EPS | -0.47 | -0.15 | -0.48 | -0.55 | -0.53 |
| EPS Diluted | -0.75 | -0.24 | -0.77 | -0.88 | -0.84 |
| Normalized Diluted EPS | -0.47 | -0.15 | -0.48 | -0.55 | -0.53 |
| Average Basic Shares Outstanding | 42.87M | 42.26M | 38.34M | 32.72M | 32.49M |
| Average Diluted Shares Outstanding | 42.87M | 42.26M | 38.34M | 32.72M | 32.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
